Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Gastrointestinal 1Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Prostatic Neoplasms 4Neoplasms 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoma, Follicular 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Metastatic Castration-resistant Prostate Cancer 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Lymphoma 2Hodgkin Disease 2Endometrial Neoplasms 2Down Syndrome 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myasthenia Gravis 1Lymphoma, T-Cell, Peripheral 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Biliary Tract Neoplasms 1Adrenal Insufficiency 1

Interventions

Bevacizumab 35Paclitaxel 31Carboplatin 24pembrolizumab 23Specimen Handling 21Magnetic Resonance Spectroscopy 19Gemcitabine 18olaparib 16liposomal doxorubicin 16Cyclophosphamide 15fludarabine 12Topotecan 12Biopsy 12niraparib 11Cisplatin 10Taxes 8Nivolumab 8Immunoglobulin G 8Fulvestrant 8Disulfides 8Doxorubicin 7aldesleukin 6Surveys and Questionnaires 6palbociclib 5Oxaliplatin 5Fluorouracil 5trastuzumab deruxtecan 4oregovomab 4mirvetuximab soravtansine 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Prednisolone × 90 days × Clear all
NCT04300556 2026-06-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Eisai Inc.

Phase 1/2 Recruiting
182 enrolled
BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06421935 2026-03-24

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

EMD Serono

Phase 1 Active not recruiting
141 enrolled
Gynecologic

Ovarian Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

Phase 2 Recruiting
454 enrolled
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡